Beyond Cancer Sees 6 of 10 Patients Alive 22-40 Months Post-UNO; Patent Allowance Granted
Six of ten heavily pretreated solid tumor patients remain alive 22 to 40 months after a single intratumoral UNO injection in the Phase 1 trial, with two triple negative breast cancer cases showing no evidence of disease. Treatment was generally well tolerated and a U.S. patent allowance was received.
1. Trial Design and Patient Profile
The Phase 1 proof-of-concept trial enrolled ten heavily pretreated patients with unresectable cutaneous or subcutaneous lesions, including six breast cancer, two squamous cell carcinoma and two melanoma cases, all having received a median of four prior systemic therapies and 11 total cancer-directed treatments.
2. Survival and Safety Outcomes
As of the last follow-up, six patients remain alive between 22 and 40 months after a single intratumoral UNO injection; two triple negative breast cancer subjects show no evidence of disease. Adverse events were predominantly Grade 1 or 2, with one reversible hypoxia event at 25,000 ppm that was not dose-limiting.
3. Patent Allowance and IP Strengthening
A U.S. Patent and Trademark Office Notice of Allowance was issued for the proprietary gas delivery system used in UNO, pending formal issuance, which will bolster the intellectual property portfolio and support further clinical development and potential commercialization.